Hospitals

Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial

May 17, 2016

 

BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE) (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the fields of bone fracture repair, fracture prevention and spinal fusion, today announces positive efficacy results for the second patient cohort in the Phase I/IIA trial of its allogeneic1 bone cell therapy product ALLOB® for the treatment of delayed-union fractures. Eight patients have now been treated and of these, seven patients met the primary endpoints of the trial within the six-month follow-up period2.

The ongoing Phase I/IIA study is a six-month open-label trial to evaluate the safety and efficacy of ALLOB® in the treatment of delayed-union fractures of long bones. Patients receive a single percutaneous administration of ALLOB® directly into the fracture site. The study is targeting the recruitment of 32 patients, but is flexible and could be prematurely stopped on the basis of efficacy after an interim data analysis of the first 16 patients. To date, eight patients with a fracture that had failed to consolidate after a minimum of three and a maximum of seven months, have completed the six-month follow-up without any treatment-related safety concerns.

Fracture healing is assessed using radiological and clinical (e.g., pain, weight bearing) evaluation. In this cohort of eight patients, radiological scores showed a statistically significant improvement of 77% at six months. Overall, pain at the fracture site improved by 68% and health status by 50% at six months (all statistically significant). Additional follow-up of the first four patients confirms the efficacy and patient’s minimal pain and good health status at 12 months.

Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: “We are pleased to report that these efficacy data for the second cohort are in line with the positive results communicated for the first and come alongside confirmation of safety in the trial. The clinical and radiological improvements demonstrate that a single administration of ALLOB® can offer significant benefits for these patients and strengthen our belief in the value of this allogeneic ‘off the shelf’ product.”

1 Allogeneic”, or “off the shelf” therapies are those in which the cells are harvested from a healthy donors, as opposed to “autologous” where the cells come from the patient him/herself.
2 The lack of a response in one patient could be related to an instability of the fixation devices of the fracture.

  • About ALLOB®

ALLOB® is a first-in-class allogeneic differentiated osteoblastic (bone-forming) cell therapy product developed for the treatment of orthopaedic conditions and bone diseases. Allogeneic cell therapy involves the harvesting of cells from a healthy donor, rather than from the treated patient. ALLOB® is currently being evaluated in three Phase I/IIA clinical trials for delayed-union fractures, spinal fusion and the revision of failed spinal fusions. ALLOB® has been classified as a tissue engineered product under the ATMP regulation 1394/2007EMA and received orphan drug designation from the EMA (Europe) and FDA (US) for two indications, osteonecrosis and osteogenesis imperfecta.

  • About Delayed-Union Fractures

A delayed-union fracture is defined as a fracture that has not healed within the expected normal period after the initial injury (i.e. 3 to 4 months) and is at risk of non-healing. Traditional options for the treatment of an impaired fracture (i.e. bone graft) typically involve highly invasive surgery, which can be painful and require months of rehabilitation with the risk of serious complications. Due to the risks of current treatments, orthopaedic surgeons often take a ‘wait-and-see’ approach, sometimes for several months, which delays the patient’s return to a normal life and leads to a significant burden on society. ALLOB® has the potential to become a first-line and early treatment for delayed-union fractures, thanks to its minimally invasive administration that avoids the need for major surgery. Bone Therapeutics has already demonstrated efficacy in the first four-patient cohort of its ALLOB® Phase I/IIA trial for delayed-union fractures and completed treatment without any safety concerns in the second cohort.

  • About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine, including a minimally invasive therapy for failed spinal fusions. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at: www.bonetherapeutics.com.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts

For further information, please contact:
Bone Therapeutics SA
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
+32 (0)2 529 59 90
investorrelations@bonetherapeutics.com
or
For Belgium and International Media Enquiries:
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson and Hendrik Thys, +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
or
For French Media and Investor Enquiries:
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau, + 33 (0)1 44 71 94 94
bone@newcap.eu

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close